NMOSD medication not recommended for the PBS for a second time
7 January 2022
Soliris® (eculizumab), the first TGA-approved medication for NMOSD, has not been recommended for listing on the PBS.
Soliris® (eculizumab), the first TGA-approved medication for NMOSD, has not been recommended for listing on the PBS.
New imaging data shows sustained improvement in disability and increases in myelin density in the brain following an experimental treatment for progressive MS.
CEO Rohan Greenland gives an update on the MS Australia activities for December, focusing on the year ahead for MS Australia.
We look back on the enormous milestones reached in 2021 thanks to the Kiss Goodbye to MS community. Thank you for continuing to accelerate our superpower – MS research.
A recent study from regional NSW is the first to assess if the NDIS package allocated to people with MS matches the level of disability measured by a formal neurological assessment.
A new study of brain tissue has found that immune cells derived from blood immune cells, attack myelin in the very early stages of MS.
MS Australia National Advocate Erin Brady reflects on International Day of People with Disability in a post-pandemic world.
Our Kiss Goodbye to MS ambassadors say thank you to the fantastic MS community by sharing their very own thank you letters.
MS researchers have investigated whether a naturally occurring molecule, which some DMTs mimic, has the capacity to promote myelin repair.